Interviews

Sam Peasah, PhD, MBA, RPh, director of High-Value Health Care Value-Based Pharmacy Initiatives at UPMC Health Plan, shares findings from a study on the cost impact of achieving 80% adherence to newer antidiabetic agents.

Findings presented at the American College of Cardiology Annual Scientific Session indicate that finerenone's efficacy in reducing cardiovascular death did not significantly differ across baseline bilirubin tertiles.

Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth, discusses strategies for managing costs of novel cellular and gene therapies in the oncology pipeline.

Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida, discusses gene therapy considerations for pediatric patients and how newborn screening can influence outcomes for patients with Duchenne muscular dystrophy (DMD).

JC Scott, CEO and president of The Pharmaceutical Care Management Association, discusses the evolving role pharmacy benefit managers (PBMs) play in addressing payer, provider, and patient needs.

Caspian Oliai, MD, MS, medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center, discusses findings from the phase 3 Precision-T trial of Orca-T in acute leukemia and myelodysplastic syndrome (MDS).

Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth, shares key components that makes a value-based contract successful.

Adam Colborn, JD, associate vice president for congressional affairs, AMCP, discusses key regulatory factors that managed care professionals must consider when implementing artificial intelligence (AI) in practice.

In part 1 of this interview with Katrina Ortblad, ScD, MPH, she addressed bridging gaps in HIV care with pharmacy-based solutions.

In part 3 of a discussion with Andrew Kuykendall, MD, Moffitt Cancer Center, he talks of rusfertide’s ability to enable patients to live a more viable life and free them from being tethered to the need for regular phlebotomies.

The long-term impact of disruptions in oncology care during the COVID-19 pandemic will become more apparent in the coming years, according to Dan Nardi, MS, of Reimagine Care.

Anna Mueller, MD, Mount Sinai, presented the findings at the American College of Cardiology 2025 Annual Scientific Session and explained that broader adoption of imaging assessments will depend on further research.

Another study testing sotatercept as an early intervention for pulmonary arterial hypertension (PAH) is anticipated to determine the effect on outcomes, Marc Humbert, MD, PhD, University Paris-Saclay, explains in an interview.

Susan Cantrell, CEO of the Academy of Managed Care Pharmacy, breaks down some of the key conference topics that will be discussed at this year's meeting.

At the American College of Cardiology 2025 Annual Scientific Session, John W. Ostrominski, MD, of Brigham and Women’s Hospital, dives into the nuanced safety profile of finerenone for high-risk patients with heart failure.

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.

STRIDE investigator Marc Bonaca, MD, MPH, University of Colorado School of Medicine, highlights how the data could provide insight into peripheral artery disease and type 2 diabetes treatment options.

Christian T. Ruff, MD, MPH, of Brigham and Women's Hospital, discusses new data comparing abelacimab with rivaroxaban in patients with atrial fibrillation presented at the American College of Cardiology 2025 Annual Scientific Session.

Although the widespread adoption of remote patient monitoring during the COVID-19 pandemic expanded care access, particularly for underserved communities, challenges persist in sustaining this access.

Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of understanding inflammatory pathways for developing targeted therapies.

For higher-risk multiple myeloma (MM), successful patient selection and monitoring strategies are vital for the management of adverse events and the disease itself.

Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council, highlights upcoming discussions on patient engagement, formulary management, and policy changes, including the Inflation Reduction Act.

Joshua Kaufman, MD, of CDPHP, discusses the significance of long-acting injectables (LAIs) in improving adherence, reducing the risk of relapse, and preventing hospitalizations.

The approval of revakinagene taroretcel (Encelto; Neurotech) addresses a significant unmet need for patients with macular telangiectasia type 2 (MacTel), clinical investigator Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, said.

Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, advocates for increased funding and education to address hair loss disparities within the African diaspora, emphasizing the need for culturally sensitive treatment and research.

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, discusses data supporting the FDA approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals), the first and only therapy indicated for the treatment of macular telangiectasia type 2 (MacTel).

One of the major highlights of the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference is that invaluable networking opportunities can help clinicians elevate their own best practices.

In this discussion with Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, she illustrates how Vanderbilt works to specify each individual patient’s cancer care regimen and treatment path.

Lipoprotein(a) [Lp(a)] plays a key role in assessing cardiovascular risk, making awareness efforts equally essential for prevention and early intervention.

Elizabeth Jones, MD, FAAD, highlights the persistent issue of insurance companies favoring expensive, newer medications over equally effective generics in dermatology, emphasizing the time-consuming prior authorization process and advocating for patient partnerships and systemic improvements.